December 23, 2020

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
Press release

December 9, 2020

HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease

Cytotherapy

December 4, 2020

Re-examination of MAGE-A3 as a T-cell Therapeutic Target
Journal of Immunotherapy

November 9, 2020

A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro

PLOS ONE

November 4, 2020

Cancer T-cell Therapy: Building the Foundation for a Cure

F1000Research

October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

Press release

October 2, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

Molecular Immunology

October 1, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

3rd Cell Therapies and Immunotherapy Conference

August 31,  2020

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

The Essential Protein Engineering & Cell Therapy Summit Virtual

August 5, 2020

Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen

Molecular Immunology

November 21, 2019

Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs

Scientific Reports

November 5, 2019

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics

Press release